These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 20571232)

  • 41. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
    Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
    Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer.
    Yigit E; Gönüllü G; Yücel I; Turgut M; Erdem D; Cakar B
    Eur J Intern Med; 2008 Dec; 19(8):602-7. PubMed ID: 19046726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level.
    Park IJ; Choi GS; Lim KH; Kang BM; Jun SH
    Ann Surg Oncol; 2009 Nov; 16(11):3087-93. PubMed ID: 19629600
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
    Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
    Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
    Kuroda N; Kontani K; Kajikawa T; Taminato T
    Rinsho Byori; 2010 Jun; 58(6):541-52. PubMed ID: 20662264
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
    Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
    Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The carcinoembryonic antigen as a potential prognostic marker for neuroendocrine carcinoma of the breast.
    Su CH; Chang H; Chen CJ; Liu LC; Wang HC; Lane HY; Bau DT
    Anticancer Res; 2012 Jan; 32(1):183-8. PubMed ID: 22213305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ.
    Stackievicz R; Paran H; Bernheim J; Shapira M; Weisenberg N; Kaufman T; Klein E; Gutman M
    Isr Med Assoc J; 2010 May; 12(5):290-5. PubMed ID: 20929083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
    van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
    N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The reflection of the dynamics of the serum markers CA l5.3 and CEA in breast cancer].
    Cianga C; Suliman I
    Rev Med Chir Soc Med Nat Iasi; 1998; 102(3-4):93-5. PubMed ID: 10756852
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: correlation with clinicopathological parameters.
    Farzadnia M; Meibodi NT; Shandiz FH; Mahmoudi M; Bahar MM; Memar B; Amoian S; Maroozi F; Moheghi N
    Breast; 2010 Dec; 19(6):489-92. PubMed ID: 20675140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The significance of CA15-3 in breast cancer patients and its relationship to HER-2 receptor status.
    Hashim ZM
    Int J Immunopathol Pharmacol; 2014; 27(1):45-51. PubMed ID: 24674678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.